Skip to main content

Advertisement

SpringerLink
Log in

Nanoparticles: A Promising Modality in the Treatment of Sarcomas

  • Expert Review
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Improvements in surgical technique, chemotherapy, and radiotherapy have enhanced the prognosis of sarcoma patients, but have since reached a plateau in recent years. Novel approaches have been sought but with limited results. Nanomedicine offers solutions in diverse areas of sarcoma therapy including diagnosis and treatment. Several varieties of nanoparticles, including multifunctional nanoparticles, are available that localize the biodistribution of conventional chemotherapeutics to the tumor site. Also, nanoparticles loaded with chemotherapeutic drugs have the ability to overcome drug resistance which is a major obstacle impeding the progress of the treatment. Multifunctional nanoparticles, which have the potential to further augment the bioavailability of drugs, are being actively investigated. In this review, we will discuss the application of nanoparticles for improving the treatment of sarcoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

REFERENCES

  1. Fletcher CDM, Unni KK, Mertens F. World Health Organization classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC; 2002.

    Google Scholar 

  2. Miller RW, Young Jr JL, Novakovic B. Childhood cancer. Cancer. 1995;75:395–405.

    CAS  PubMed  Google Scholar 

  3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

    PubMed  Google Scholar 

  4. Fayette J, Penel N, Chevreau C, Blay JY, Cupissol D, Thyss A, et al. Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs. 2009;27:482–9.

    CAS  PubMed  Google Scholar 

  5. Eselgrim M, Grunert H, Kuhne T, Zoubek A, Kevric M, Burger H, et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer. 2006;47:42–50.

    PubMed  Google Scholar 

  6. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112–28.

    CAS  PubMed  Google Scholar 

  7. Helmanand LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer. 2003;3:685–94.

    Google Scholar 

  8. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.

    CAS  PubMed  Google Scholar 

  9. Brasseur F, Couvreur P, Kante B, Deckers-Passau L, Roland M, Deckers C, et al. Actinomycin D absorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumor. Eur J Cancer. 1980;16:1441–5.

    CAS  PubMed  Google Scholar 

  10. Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci. 2006;27:27–36.

    CAS  PubMed  Google Scholar 

  11. Fang J, Deng D, Nakamura H, Akuta T, Qin H, Iyer AK, et al. Oxystress inducing antitumor therapeutics via tumor-targeted delivery of PEG-conjugated D-amino acid oxidase. Int J Cancer. 2008;122:1135–44.

    CAS  PubMed  Google Scholar 

  12. Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem. 2004;11:413–24.

    CAS  PubMed  Google Scholar 

  13. Gipps EM, Arshady R, Kreuter J, Groscurth P, Speiser PP. Distribution of polyhexyl cyanoacrylate nanoparticles in nude mice bearing human osteosarcoma. J Pharm Sci. 1986;75:256–8.

    CAS  PubMed  Google Scholar 

  14. He M, Zhao Z, Yin L, Tang C, Yin C. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. Int J Pharm. 2009;373:165–73.

    CAS  PubMed  Google Scholar 

  15. Kreuterand J, Hartmann HR. Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice. Oncology. 1983;40:363–6.

    Google Scholar 

  16. Susa M, Iyer AK, Ryu K, Hornicek FJ, Mankin H, Amiji MM, et al. Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma. BMC Cancer. 2009;9:399.

    PubMed  Google Scholar 

  17. Hori K, Nishihara M, Yokoyama M. Vital microscopic analysis of polymeric micelle extravasation from tumor vessels: macromolecular delivery according to tumor vascular growth stage. J Pharm Sci. 2009.

  18. Messerschmidt SK, Musyanovych A, Altvater M, Scheurich P, Pfizenmaier K, Landfester K, et al. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Release. 2009;137:69–77.

    CAS  PubMed  Google Scholar 

  19. Udhrain A, Skubitz KM, Northfelt DW. Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma. Int J Nanomedicine. 2007;2:345–52.

    CAS  PubMed  Google Scholar 

  20. Zheng J, Jaffray D, Allen C. Quantitative CT imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model. Mol Pharm. 2009;6:571–80.

    CAS  PubMed  Google Scholar 

  21. Kaminskas LM, Kelly BD, McLeod VM, Boyd BJ, Krippner GY, Williams ED, et al. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. Mol Pharm. 2009;6:1190–204.

    CAS  PubMed  Google Scholar 

  22. Wang C, Ma Q, Dou W, Kanwal S, Wang G, Yuan P, et al. Synthesis of aqueous CdTe quantum dots embedded silica nanoparticles and their applications as fluorescence probes. Talanta. 2009;77:1358–64.

    CAS  PubMed  Google Scholar 

  23. Zhang Y, So MK, Rao J. Protease-modulated cellular uptake of quantum dots. Nano Lett. 2006;6:1988–92.

    CAS  PubMed  Google Scholar 

  24. Cai QY, Kim SH, Choi KS, Kim SY, Byun SJ, Kim KW, et al. Colloidal gold nanoparticles as a blood-pool contrast agent for X-ray computed tomography in mice. Invest Radiol. 2007;42:797–806.

    CAS  PubMed  Google Scholar 

  25. Li XS, Li WQ, Wang WB. Using targeted magnetic arsenic trioxide nanoparticles for osteosarcoma treatment. Cancer Biother Radiopharm. 2007;22:772–8.

    PubMed  Google Scholar 

  26. Rapoport N. Combined cancer therapy by micellar-encapsulated drug and ultrasound. Int J Pharm. 2004;277:155–62.

    CAS  PubMed  Google Scholar 

  27. Yang SJ, Chang SM, Tsai KC, Chen WS, Lin FH, Shieh MJ. Effect of chitosan-alginate nanoparticles and ultrasound on the efficiency of gene transfection of human cancer cells. J Gene Med. 2009;12:168–79.

    Google Scholar 

  28. Fretz MM, Hogset A, Koning GA, Jiskoot W, Storm G. Cytosolic delivery of liposomally targeted proteins induced by photochemical internalization. Pharm Res. 2007;24:2040–7.

    CAS  PubMed  Google Scholar 

  29. Dvir T, Banghart MR, Timko BP, Langer R, Kohane DS. Photo-targeted nanoparticles. Nano Lett. 10:250–254.

  30. Pradhan P, Giri J, Rieken F, Koch C, Mykhaylyk O, Doblinger M, et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release. 2009.

  31. Gaber MH. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia. J Biochem Mol Biol Biophys. 2002;6:309–14.

    CAS  PubMed  Google Scholar 

  32. Yatvin MB, Kreutz W, Horwitz BA, Shinitzky M. pH-sensitive liposomes: possible clinical implications. Science. 1980;210:1253–5.

    CAS  PubMed  Google Scholar 

  33. Chen QR, Zhang L, Luther PW, Mixson AJ. Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles. Nucleic Acids Res. 2002;30:1338–45.

    CAS  PubMed  Google Scholar 

  34. Pichon C, Roufai MB, Monsigny M, Midoux P. Histidylated oligolysines increase the transmembrane passage and the biological activity of antisense oligonucleotides. Nucleic Acids Res. 2000;28:504–12.

    CAS  PubMed  Google Scholar 

  35. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683–93.

    CAS  PubMed  Google Scholar 

  36. Iagaru A, Masamed R, Keesara S, Conti PS. Breast MRI and 18F FDG PET/CT in the management of breast cancer. Ann Nucl Med. 2007;21:33–8.

    PubMed  Google Scholar 

  37. Kjaer A. Molecular imaging of cancer using PET and SPECT. Adv Exp Med Biol. 2006;587:277–84.

    PubMed  Google Scholar 

  38. Lee JH, Huh YM, Jun YW, Seo JW, Jang JT, Song HT, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2007;13:95–9.

    CAS  PubMed  Google Scholar 

  39. Wang W, Ke S, Wu Q, Charnsangavej C, Gurfinkel M, Gelovani JG, et al. Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol Imaging. 2004;3:343–51.

    CAS  PubMed  Google Scholar 

  40. Mahmoodand U, Weissleder R. Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther. 2003;2:489–96.

    Google Scholar 

  41. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med. 1996;2:979–84.

    CAS  PubMed  Google Scholar 

  42. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969–76.

    CAS  PubMed  Google Scholar 

  43. Cai W, Shin DW, Chen K, Gheysens O, Cao Q, Wang SX, et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 2006;6:669–76.

    CAS  PubMed  Google Scholar 

  44. Sjogren CE, Johansson C, Naevestad A, Sontum PC, Briley-Saebo K, Fahlvik AK. Crystal size and properties of superparamagnetic iron oxide (SPIO) particles. Magn Reson Imaging. 1997;15:55–67.

    CAS  PubMed  Google Scholar 

  45. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res. 2000;60:4251–5.

    CAS  PubMed  Google Scholar 

  46. Carmelietand P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.

    Google Scholar 

  47. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207.

    CAS  PubMed  Google Scholar 

  48. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol. 1996;36:55–63.

    CAS  PubMed  Google Scholar 

  49. Minko T, Kopeckova P, Kopecek J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer. 2000;86:108–17.

    CAS  PubMed  Google Scholar 

  50. Omelyanenko V, Gentry C, Kopeckova P, Kopecek J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer. 1998;75:600–8.

    CAS  PubMed  Google Scholar 

  51. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002;20:1668–76.

    CAS  PubMed  Google Scholar 

  52. Morizono K, Xie Y, Ringpis GE, Johnson M, Nassanian H, Lee B, et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med. 2005;11:346–52.

    CAS  PubMed  Google Scholar 

  53. Saul JM, Annapragada AV, Bellamkonda RV. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release. 2006;114:277–87.

    CAS  PubMed  Google Scholar 

  54. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 1988;48:1926–9.

    CAS  PubMed  Google Scholar 

  55. van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, et al. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol. 1990;1:56–64.

    PubMed  Google Scholar 

  56. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994;83:2451–8.

    CAS  PubMed  Google Scholar 

  57. Licht T, Pastan I, Gottesman M, Herrmann F. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann Hematol. 1994;69:159–71.

    CAS  PubMed  Google Scholar 

  58. Chaudharyand PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991;66:85–94.

    Google Scholar 

  59. Gottesmanand MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427.

    Google Scholar 

  60. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998;95:15665–70.

    CAS  PubMed  Google Scholar 

  61. Smeets M, Raymakers R, Vierwinden G, Pennings A, van de Locht L, Wessels H, et al. A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity. Br J Haematol. 1997;96:346–55.

    CAS  PubMed  Google Scholar 

  62. Jonkersand J, Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell. 2004;6:535–8.

    Google Scholar 

  63. Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, et al. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther. 2009;8:2122–30.

    CAS  PubMed  Google Scholar 

  64. Zhang W, Lee JC, Kumar S, Gowen M. ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells. J Bone Miner Res. 1999;14:528–35.

    CAS  PubMed  Google Scholar 

  65. Toretsky JA, Steinberg SM, Thakar M, Counts D, Pironis B, Parente C, et al. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer. 2001;92:2941–7.

    CAS  PubMed  Google Scholar 

  66. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:1190–7.

    PubMed  Google Scholar 

  67. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005;65:3868–76.

    CAS  PubMed  Google Scholar 

  68. Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2005;23:6172–80.

    CAS  PubMed  Google Scholar 

  69. Hughes DP, Thomas DG, Giordano TJ, McDonagh KT, Baker LH. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer. 2006;46:614–23.

    PubMed  Google Scholar 

  70. Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67:919–29.

    CAS  PubMed  Google Scholar 

  71. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 2007;67:2800–8.

    CAS  PubMed  Google Scholar 

  72. Sebolt-Leopoldand JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4:937–47.

    Google Scholar 

  73. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4:677–85.

    CAS  PubMed  Google Scholar 

  74. Bozzi F, Tamborini E, Negri T, Pastore E, Ferrari A, Luksch R, et al. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors. Cancer. 2007;109:1638–45.

    CAS  PubMed  Google Scholar 

  75. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing’s Sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst. 2002;94:1673–9.

    CAS  PubMed  Google Scholar 

  76. Cen L, Hsieh FC, Lin HJ, Chen CS, Qualman SJ, Lin J. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer. 2007;97:785–91.

    CAS  PubMed  Google Scholar 

  77. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, Zhou L, et al. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer. 2002;102:338–42.

    CAS  PubMed  Google Scholar 

  78. Warzecha J, Gottig S, Chow KU, Bruning C, Percic D, Boehrer S, et al. Inhibition of osteosarcoma cell proliferation by the Hedgehog-inhibitor cyclopamine. J Chemother. 2007;19:554–61.

    CAS  PubMed  Google Scholar 

  79. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res. 2008;14:2962–9.

    CAS  PubMed  Google Scholar 

  80. Duan Z, Ji D, Weinstein EJ, Liu X, Susa M, Choy E, et al. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. Cancer Lett.

  81. Yang C, Ji D, Weinstein EJ, Choy E, Hornicek FJ, Wood KB, et al. The Kinase Mirk is a Potential Therapeutic Target in Osteosarcoma. Carcinogenesis. 2009.

  82. Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, et al. Suppression of Ewing’s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res. 2007;13:4867–73.

    CAS  PubMed  Google Scholar 

  83. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:581–7.

    PubMed  Google Scholar 

  84. Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati BK, Kompella UB. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009;15:7299–308.

    CAS  PubMed  Google Scholar 

  85. Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci USA. 2009;106:7957–61.

    CAS  PubMed  Google Scholar 

  86. Harfouche R, Basu S, Soni S, Hentschel DM, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis. 2009;12:325–38.

    CAS  PubMed  Google Scholar 

  87. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–11.

    CAS  PubMed  Google Scholar 

  88. Dykxhoornand DM, Lieberman J. Knocking down disease with siRNAs. Cell. 2006;126:231–5.

    Google Scholar 

  89. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001;15:188–200.

    CAS  PubMed  Google Scholar 

  90. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, et al. Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 2005;12:437–45.

    CAS  PubMed  Google Scholar 

  91. Toub N, Bertrand JR, Tamaddon A, Elhamess H, Hillaireau H, Maksimenko A, et al. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res. 2006;23:892–900.

    CAS  PubMed  Google Scholar 

  92. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA. 2007;104:5715–21.

    CAS  PubMed  Google Scholar 

  93. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.

    CAS  PubMed  Google Scholar 

  94. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta. 2007;1775:237–62.

    CAS  PubMed  Google Scholar 

  95. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res. 1999;5:3352–6.

    CAS  PubMed  Google Scholar 

  96. Yague E, Arance A, Kubitza L, O’Hare M, Jat P, Ogilvie CM, et al. Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res. 2007;67:1130–7.

    PubMed  Google Scholar 

  97. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182–90.

    CAS  PubMed  Google Scholar 

  98. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol. 2001;115:895–902.

    CAS  PubMed  Google Scholar 

  99. Twentymanand PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer. 1991;27:1639–42.

    Google Scholar 

  100. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004;22:4290–301.

    CAS  PubMed  Google Scholar 

  101. Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics. 2005;6:115–38.

    CAS  PubMed  Google Scholar 

  102. Kobayashi H, Dorai T, Holland JF, Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 1994;54:1271–5.

    CAS  PubMed  Google Scholar 

  103. Stuart DD, Kao GY, Allen TM. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther. 2000;7:466–75.

    CAS  PubMed  Google Scholar 

  104. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003;63:1515–9.

    CAS  PubMed  Google Scholar 

  105. Yadav S, van Vlerken LE, Little SR, Amiji MM. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol. 2009;63:711–22.

    CAS  PubMed  Google Scholar 

  106. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 31:358–365.

  107. Devalapally H, Duan Z, Seiden MV, Amiji MM. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res. 2008;14:3193–203.

    CAS  PubMed  Google Scholar 

  108. Tirino V, Desiderio V, d’Aquino R, De Francesco F, Pirozzi G, Graziano A, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One. 2008;3:e3469.

    PubMed  Google Scholar 

  109. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 2005;7:967–76.

    CAS  PubMed  Google Scholar 

  110. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, et al. Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res. 2009;69:1776–81.

    CAS  PubMed  Google Scholar 

  111. Fiala S. The cancer cell as a stem cell unable to differentiate. A theory of carcinogenesis. Neoplasma. 1968;15:607–22.

    CAS  PubMed  Google Scholar 

  112. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.

    CAS  PubMed  Google Scholar 

  113. Yang M, Zhang R, Yan M, Ye Z, Liang W, Luo Z. Detection and characterization of side population in Ewing’s sarcoma SK-ES-1 cells in vitro. Biochem Biophys Res Commun. 391:1062–1066.

  114. Pierce GB. The cancer cell and its control by the embryo. Rous-Whipple Award lecture. Am J Pathol. 1983;113:117–24.

    CAS  PubMed  Google Scholar 

  115. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444:761–5.

    CAS  PubMed  Google Scholar 

  116. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672–9.

    CAS  PubMed  Google Scholar 

  117. Lotemand J, Sachs L. Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene. 2006;25:7663–72.

    Google Scholar 

  118. Jonesand PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92.

    Google Scholar 

  119. Petersen C, Zips D, Krause M, Schone K, Eicheler W, Hoinkis C, et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys. 2001;51:483–93.

    CAS  PubMed  Google Scholar 

  120. Petersen C, Zips D, Krause M, Volkel W, Thames HD, Baumann M. Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. Radiother Oncol. 2005;74:331–6.

    PubMed  Google Scholar 

  121. Baumann M, Dubois W, Suit HD. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. Radiat Res. 1990;123:325–30.

    CAS  PubMed  Google Scholar 

  122. Yaromina A, Krause M, Thames H, Rosner A, Hessel F, Grenman R, et al. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol. 2007;83:304–10.

    CAS  PubMed  Google Scholar 

  123. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60.

    CAS  PubMed  Google Scholar 

  124. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780–3.

    CAS  PubMed  Google Scholar 

  125. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature. 2009;457:51–6.

    CAS  PubMed  Google Scholar 

  126. Tokumitsu H, Hiratsuka J, Sakurai Y, Kobayashi T, Ichikawa H, Fukumori Y. Gadolinium neutron-capture therapy using novel gadopentetic acid-chitosan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor. Cancer Lett. 2000;150:177–82.

    CAS  PubMed  Google Scholar 

  127. Fujimoto T, Ichikawa H, Akisue T, Fujita I, Kishimoto K, Hara H, et al. Accumulation of MRI contrast agents in malignant fibrous histiocytoma for gadolinium neutron capture therapy. Appl Radiat Isot. 2009;67:S355–8.

    CAS  PubMed  Google Scholar 

  128. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, et al. Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 1995;60:183–9.

    CAS  PubMed  Google Scholar 

  129. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001;2:293–9.

    CAS  PubMed  Google Scholar 

  130. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.

    CAS  PubMed  Google Scholar 

  131. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102:18538–43.

    CAS  PubMed  Google Scholar 

  132. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59–73.

    CAS  PubMed  Google Scholar 

  133. Pritchard-Jones K, Spendlove I, Wilton C, Whelan J, Weeden S, Lewis I, et al. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br J Cancer. 2005;92:1358–65.

    CAS  PubMed  Google Scholar 

  134. Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol. 2002;38:158–64.

    PubMed  Google Scholar 

  135. Kawaguchi S, Wada T, Ida K, Sato Y, Nagoya S, Tsukahara T, et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med. 2005;3:1.

    PubMed  Google Scholar 

Download references

ACKNOWLEDGEMENTS

This project was supported, in part, by a grant from the National Cancer Institute, NIH (Nanotechnology Platform Partnership), R01-CA119617. Dr. Duan is supported, in part, through a grant from the Sarcoma Foundation of America. Support has also been provided by the Gattegno and Wechsler funds.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts, 02114, USA

    Michiro Susa, Francis J. Hornicek & Zhenfeng Duan

  2. Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, 70 Blossom Street, MGR J1115, Boston, Massachusetts, 02114, USA

    Michiro Susa, Francis J. Hornicek & Zhenfeng Duan

  3. Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts, 02115, USA

    Lara Milane & Mansoor M. Amiji

Authors
  1. Michiro Susa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lara Milane
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mansoor M. Amiji
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francis J. Hornicek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhenfeng Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhenfeng Duan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Susa, M., Milane, L., Amiji, M.M. et al. Nanoparticles: A Promising Modality in the Treatment of Sarcomas. Pharm Res 28, 260–272 (2011). https://doi.org/10.1007/s11095-010-0173-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-010-0173-z

KEY WORDS

Search

Navigation